Literature DB >> 3933203

Tetravalent (A, C, Y, W 135) meningococcal vaccine in children: immunogenicity and safety.

M Cadoz, J Armand, F Arminjon, R Gire, C Lafaix.   

Abstract

Tetravalent meningococcal polysaccharide vaccine (groups A, C, Y and W 135) was administered (s.c.) to 26 healthy children, aged three to 13 years old, in order to assess safety and immunogenicity of the vaccine. Side effects were very mild in all children, generally consisting of local soreness for a few hours following injection. A fourfold increase in bactericidal antibody titres was obtained for the four components in 100% of initially seronegative children. This vaccine thus appears as safe and immunogenic in children as it is in adults.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933203     DOI: 10.1016/s0264-410x(85)90266-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine.

Authors:  S E Maslanka; J W Tappero; B D Plikaytis; R S Brumberg; J K Dykes; L L Gheesling; K B Donaldson; A Schuchat; J Pullman; M Jones; J Bushmaker; G M Carlone
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

5.  Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.

Authors:  Duzhang Zhu; Ying Zhang; Vicki Barniak; Liesel Bernfield; Alan Howell; Gary Zlotnick
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Serologic responses to ACYW135 polysaccharide meningococcal vaccine in Saudi children under 5 years of age.

Authors:  Y Al-Mazrou; M Khalil; R Borrow; P Balmer; J Bramwell; G Lal; N Andrews; M Al-Jeffri
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 7.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

8.  Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease.

Authors:  D M Granoff; S K Kelsey; H A Bijlmer; L Van Alphen; J Dankert; R E Mandrell; F H Azmi; R J Scholten
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Clonotypic analysis of human antibodies specific for Neisseria meningitidis polysaccharides A and C in adults.

Authors:  S Le Moli; P M Matricardi; I Quinti; T Stroffolini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

10.  Adverse events temporally associated with meningococcal vaccines.

Authors:  A Yergeau; L Alain; R Pless; Y Robert
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.